▼Omalizumab for severe asthma?

Drug and Therapeutics Bulletin

Volumn 44, Issue 11, 2006, Pages 86-88

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; IMMUNOGLOBULIN E; LONG ACTING DRUG; OMALIZUMAB; PLACEBO; ANTIASTHMATIC AGENT; MONOCLONAL ANTIBODY;

ADD ON THERAPY; ALLERGIC ASTHMA; ARTICLE; ASTHMA; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; FORCED EXPIRATORY VOLUME; HUMAN; INJECTION SITE REACTION; LUNG FUNCTION; META ANALYSIS; PREGNANCY; PRICK TEST; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT WITHDRAWAL; REVIEW;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; CLINICAL TRIALS; HUMANS;

EID: 33750872001     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2006.441186     Document Type: Article

References (21)

1. Proceedings of the ATS workshop on refractory asthma. Current understanding, recommendations and unanswered questions. Am J Respir Crit Care Med 2000; 162: 2341-51.
2. Robinson DS et a]. Systematic assessment of difficult-to-treat asthma. Eur Respir J 2003; 22: 478-83.
3. Asthma UK, 2004. Where do we stand? Asthma in the UK today [online]. Available: http://www.asthma.org.uk/news_media/news/new_figures_for.html [Accessed 19 October 2006].
4. British Thoracic Society, Scottish Intercollegiate Guideline Network, 2005. British guideline on the management of asthma. A national clinical guideline [online]. Available: http://www.enterpriseportal2.co.uk/ filestore/bts/asthmaupdatenov05.pdf [Accessed 19 October 2006].
5. Holgate S et al. The ant-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005; 115: 459-65.
6. Hamelmann E et al. Role of IgE in the development of allergic airways inflammation and airways hyperresponsiveness - a murine model. Allergy 1999;54:297-305.
7. Pelikan Z, Pelikan-Filipek M. A diagnostic study of immediate hypersensitivity in asthmatic patients: a comparison of bronchial challenge and serum rast. Ann Allery 1982; 49: 112-7.
8. Presta LG et al. Humanization of an anti-body directed against IgE. J Immunol 1993; 151: 2623-32.
9. MacGlashan DW et al. Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997; 158: 1438-45.
10. Lin H et al. Omalizumab rapidly decreases nasal allergic response and Fcε_RI on basophils. J Allergy Clin Immunol 2004; 113: 297-302.
11. Djukanovic R et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004; 170: 583-93.
12. Beck LA et al. Omalizumab-induced reductions in mast cell FCεRI expression and function. J Allergy Clin Immunol 2004; 114: 527-30.
13. Prussin C et al. Omalizumab treatment downregulates dendritic cell FcεRI expression. J Allergy Clin Immunol 2003; 112: 1147-54.
14. Xolair 150mg powder and solvent for solution for injection. Summary of product characteristics, UK. Novartis Europharm Limited, October 2005.
15. Humbert M et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309-16.
16. Walker S et al. Anti-IgE for chronic asthma in adults and children. The Cochrane Database of Systematic Reviews 2006, Issue 2. Art.No.: CDO03559.pub3.DOI: 10.1002/14651858.CDO03559.pub3.
17. Bousquet J et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60: 302-8.
18. Bousquet J et al. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004; 125: 1378-86.
19. Committee for Medicinal Products for Human Use. European Public Assessment Report (ERAR). Xolair. London: European Agency for the Evaluation of Medicinal Products, 2005.
20. Scottish Medicines Consortium. Press Statement Omalizumab (Xolair®) - Novartis Pharmaceuticals UK Ltd. 12 June 2006.
21. National Institute for Health and Clinical Excellence. Omalizumab for the treatment of uncontrolled asthma [online]. Available: http://www.nice.org.uk/page.aspx?o=appraisals.inprogress.xolairasthma [Accessed 19 October 2006].